Acrivon Therapeutics (ACRV) risk factors

Item 1A of every Acrivon Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open ACRV in Gloom →

Acrivon Therapeutics' chart, financials and news, free in your browser.Open ACRV in Gloom →

FY2025 10-K risk factors
95 risks3 new1 dropped3 reworded
Acrivon Therapeutics faces new risks from evolving laboratory developed test regulations, FDA and SEC disruptions, and healthcare promotional law enforcement. The company updated its risk disclosure to reflect the May 2025 federal court ruling vacating the FDA rule on LDTs. Companion diagnostic dependencies and regulatory shifts remain critical hurdles for commercializing its pipeline.
Filed Mar 19, 2026
FY2024 10-K risk factors
93 risks
Clinical-stage biopharmaceutical company dependent on lead candidates ACR-368 and ACR-2316 developed through the AP3 platform.
Filed Mar 27, 2025